2023 Q3 Form 10-Q Financial Statement

#000173728723000076 Filed on August 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $43.00K $44.00K $86.00K
YoY Change -12.24% -48.84% 95.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.04M $18.52M $19.51M
YoY Change -9.83% -5.05% 3.87%
% of Gross Profit
Research & Development $45.98M $62.04M $57.17M
YoY Change -27.76% 8.51% 9.33%
% of Gross Profit
Depreciation & Amortization $3.570M $3.643M $3.675M
YoY Change -7.51% -0.87% 87.31%
% of Gross Profit
Operating Expenses $63.02M $80.56M $76.68M
YoY Change -23.65% 5.06% 7.89%
Operating Profit -$62.98M -$80.52M -$76.59M
YoY Change -23.66% 5.12% 7.83%
Interest Expense $6.210M $3.778M $315.0K
YoY Change 519.76% 1099.37% -49.52%
% of Operating Profit
Other Income/Expense, Net $1.660M -$1.249M $1.492M
YoY Change -351.9% -183.71% 1504.3%
Pretax Income -$61.32M -$77.99M -$74.79M
YoY Change -26.25% 4.28% 5.43%
Income Tax
% Of Pretax Income
Net Earnings -$61.32M -$77.99M -$74.79M
YoY Change -26.26% 4.28% 5.43%
Net Earnings / Revenue -142593.02% -177247.73% -86961.63%
Basic Earnings Per Share -$0.37 -$0.53 -$0.52
Diluted Earnings Per Share -$0.37 -$0.53 -$521.6K
COMMON SHARES
Basic Shares Outstanding 167.6M shares 145.8M shares 143.6M shares
Diluted Shares Outstanding 167.6M shares 146.8M shares 143.4M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $465.5M $492.0M $490.5M
YoY Change -15.7% 0.3% -16.54%
Cash & Equivalents $69.25M $154.8M $96.04M
Short-Term Investments $396.3M $337.2M $394.5M
Other Short-Term Assets $7.900M $10.14M $22.54M
YoY Change -53.07% -55.01% 55.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $473.5M $502.1M $513.0M
YoY Change -16.8% -2.13% -14.8%
LONG-TERM ASSETS
Property, Plant & Equipment $102.8M $186.7M $204.1M
YoY Change -10.15% -8.5% 62.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.50M $62.50M $211.3M
YoY Change -62.18% -70.43% -38.63%
Other Assets $9.576M $19.67M $19.23M
YoY Change 2.11% 2.31% 229.9%
Total Long-Term Assets $238.9M $268.9M $434.6M
YoY Change -25.0% -38.14% -17.15%
TOTAL ASSETS
Total Short-Term Assets $473.5M $502.1M $513.0M
Total Long-Term Assets $238.9M $268.9M $434.6M
Total Assets $712.3M $771.0M $947.6M
YoY Change -19.74% -18.64% -15.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.205M $10.23M $9.713M
YoY Change -43.82% 5.31% -11.74%
Accrued Expenses $31.20M $44.26M $34.36M
YoY Change -15.53% 28.82% -0.95%
Deferred Revenue $236.0K $229.0K $104.0K
YoY Change -73.45% 120.19% -65.9%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.64M $54.72M $44.91M
YoY Change -22.99% 21.85% -2.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.486M $93.34M $100.8M
YoY Change -26.91% -7.38% 1666.63%
Total Long-Term Liabilities $1.486M $93.34M $100.8M
YoY Change -26.91% -7.38% 1666.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.64M $54.72M $44.91M
Total Long-Term Liabilities $1.486M $93.34M $100.8M
Total Liabilities $129.2M $148.1M $145.7M
YoY Change -12.46% 1.63% 41.57%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B -$1.400B -$1.053B
YoY Change 36.36% 32.9% 40.4%
Common Stock $2.060B $2.039B $1.871B
YoY Change 8.74% 8.98% 5.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $583.1M $622.9M $801.9M
YoY Change
Total Liabilities & Shareholders Equity $712.3M $771.0M $947.6M
YoY Change -19.74% -18.64% -15.89%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$61.32M -$77.99M -$74.79M
YoY Change -26.26% 4.28% 5.43%
Depreciation, Depletion And Amortization $3.570M $3.643M $3.675M
YoY Change -7.51% -0.87% 87.31%
Cash From Operating Activities -$55.53M -$61.86M -$42.53M
YoY Change 16.53% 45.44% 3.31%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $288.0K -$1.374M
YoY Change -108.97% -120.96% -87.4%
Acquisitions
YoY Change
Other Investing Activities -$34.26M $17.45M $55.41M
YoY Change -236.34% -68.51% 56.1%
Cash From Investing Activities -$34.27M $17.16M $54.03M
YoY Change -237.6% -68.24% 119.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.280M 89.52M 24.00K
YoY Change 301.5% 372916.67% -99.25%
NET CHANGE
Cash From Operating Activities -55.53M -61.86M -42.53M
Cash From Investing Activities -34.27M 17.16M 54.03M
Cash From Financing Activities 4.280M 89.52M 24.00K
Net Change In Cash -85.52M 44.83M 11.53M
YoY Change 294.39% 288.89% -186.29%
FREE CASH FLOW
Cash From Operating Activities -$55.53M -$61.86M -$42.53M
Capital Expenditures $20.00K $288.0K -$1.374M
Free Cash Flow -$55.55M -$62.15M -$41.16M
YoY Change 17.12% 50.99% 35.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://allogene.com/20230630#AccruedAndOtherLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://allogene.com/20230630#AccruedAndOtherLiabilitiesCurrent
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146795826 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146795826 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
916406000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
283000 usd
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1228000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22315000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
813000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22891000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-74787000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2223000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
801949000 usd
us-gaap Profit Loss
ProfitLoss
-176693000 usd
us-gaap Profit Loss
ProfitLoss
-154637000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35364000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
45206000 usd
us-gaap Depreciation
Depreciation
7150000 usd
us-gaap Depreciation
Depreciation
7367000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
566000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-2240000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
357000 usd
allo Gain Loss From Cost Method Investment
GainLossFromCostMethodInvestment
-2907000 usd
allo Gain Loss From Cost Method Investment
GainLossFromCostMethodInvestment
-2309000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1365000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8515000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
55000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2803000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3233000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
917000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5610000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3334000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-656000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
413000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-46000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1571000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128496000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110768000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1323000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3276000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5623000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
296309000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
185797000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
170514000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
150864000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130095000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31657000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
87918000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1606000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
308000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1731000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1530000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91255000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1838000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
92854000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-77273000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72196000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183606000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165050000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106333000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
31361000 usd
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
5989000 usd
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
3983000 usd
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
0 usd
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
325000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
1363000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), as amended on November 2, 2022, under which the Company may from time-to-time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0 million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through Cowen pursuant to the sales agreement. During the three months ended June 2023, the Company sold an aggregate of 20,288,330 shares of common stock in ATM offerings resulting in net proceeds of $87.9 million. As of June 30, 2023, $77.9 million remains available for sale under the sales agreement with Cowen.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents and investments of $544.5 million as of June 30, 2023. Since inception through June 30, 2023, the Company has incurred cumulative net losses of $1.4 billion. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div>The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).
CY2019Q4 allo Stock Issuance Maximum Value
StockIssuanceMaximumValue
250000000 usd
CY2019Q4 allo Stock Issuance Maximum Compensation Due To Third Party Percent
StockIssuanceMaximumCompensationDueToThirdPartyPercent
0.030
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
544500000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
541593000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3421000 usd
CY2023Q2 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
538186000 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
148396000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
337204000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
52586000 usd
CY2023Q2 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
538186000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
535809000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9512000 usd
CY2022Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
526327000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11760000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
455416000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
59151000 usd
CY2022Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
526327000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
1000000 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
191800000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
329400000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1100000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1800000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
150421000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
149724000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
44035000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36885000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106386000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112839000 usd
CY2018Q3 allo Area Of New Office Building
AreaOfNewOfficeBuilding
68000 sqft
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P127M
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2023Q2 us-gaap Tenant Improvements
TenantImprovements
5000000 usd
CY2021Q4 allo Additional Area Of New Office Building
AdditionalAreaOfNewOfficeBuilding
47566 sqft
CY2018Q4 allo Area Of New Office Building
AreaOfNewOfficeBuilding
14943 sqft
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018Q4 allo Tenant Improvement Allowance
TenantImprovementAllowance
800000 usd
CY2022Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
6000000 usd
CY2023Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
6000000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6381000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6002000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91821000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
95122000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
98202000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
101124000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3175000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3177000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6356000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
5299000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
672000 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
397000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
852000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
3847000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
3574000 usd
us-gaap Lease Cost
LeaseCost
7719000 usd
us-gaap Lease Cost
LeaseCost
6151000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
6000000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6060000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
12447000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12627000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12819000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13257000 usd
CY2023Q2 allo Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
77235000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
134445000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36243000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
98202000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0688
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y6M
CY2020Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P20Y
CY2020Q3 allo Lessee Finance Lease Payment Upon Contract Termination
LesseeFinanceLeasePaymentUponContractTermination
4300000 usd
CY2023Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
400000 usd
CY2023Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
9900000 usd
CY2022Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
12800000 usd
allo Number Of Shares As Percentage Of Common Shares Outstanding
NumberOfSharesAsPercentageOfCommonSharesOutstanding
0.05
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6377914 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
5200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.57
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16594000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22891000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35364000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45206000 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
293594 shares
CY2023Q2 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
1500000 usd
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
1900000 usd
CY2023Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
0 usd
CY2022Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
600000 usd
CY2023Q1 allo Operating Lease Base Rent And Security Deposit Payment
OperatingLeaseBaseRentAndSecurityDepositPayment
200000 usd
CY2023Q1 allo Operating Lease Total Estimated Base Rent
OperatingLeaseTotalEstimatedBaseRent
2900000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36609115 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25922078 shares

Files In Submission

Name View Source Status
0001737287-23-000076-index-headers.html Edgar Link pending
0001737287-23-000076-index.html Edgar Link pending
0001737287-23-000076.txt Edgar Link pending
0001737287-23-000076-xbrl.zip Edgar Link pending
allo-20230630.htm Edgar Link pending
allo-20230630.xsd Edgar Link pending
allo-20230630xex311.htm Edgar Link pending
allo-20230630xex312.htm Edgar Link pending
allo-20230630xex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
allo-20230630_cal.xml Edgar Link unprocessable
allo-20230630_def.xml Edgar Link unprocessable
allo-20230630_lab.xml Edgar Link unprocessable
allo-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
allo-20230630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending